Page last updated: 2024-09-04

moxifloxacin and zabofloxacin

moxifloxacin has been researched along with zabofloxacin in 3 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (zabofloxacin)	Trials (zabofloxacin)	Recent Studies (post-2010) (zabofloxacin)
3,157	552	1,690	16	3	8

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM	1
Chang, JH; Choi, EG; Kim, HK; Kwon, YS; Kyung, SY; Lee, JH; Oh, YM; Park, MJ; Rhee, CK; Yoo, KH	1
Kocsis, B; Szabo, D	1

Trials

1 trial(s) available for moxifloxacin and zabofloxacin

Article	Year
Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial. International journal of chronic obstructive pulmonary disease, 2015, Volume: 10 Topics: Aged; Anti-Bacterial Agents; Double-Blind Method; Drug Monitoring; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Outcome	2015

Article

Year

Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.

International journal of chronic obstructive pulmonary disease, 2015, Volume: 10

Topics: Aged; Anti-Bacterial Agents; Double-Blind Method; Drug Monitoring; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Outcome

2015

Other Studies

2 other study(ies) available for moxifloxacin and zabofloxacin

Article	Year
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae	2006
Zabofloxacin for chronic bronchitis. Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:9 Topics: Anti-Infective Agents; Bronchitis, Chronic; Clinical Studies as Topic; Drug Administration Routes; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Respiratory Tract Infections; Treatment Outcome	2016

Article

Year

Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6

Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae

2006

Zabofloxacin for chronic bronchitis.

Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:9

Topics: Anti-Infective Agents; Bronchitis, Chronic; Clinical Studies as Topic; Drug Administration Routes; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Respiratory Tract Infections; Treatment Outcome

2016